STEPSTONE Pharma was founded following Amgen’s $10B acquisition of Onyx Pharmaceuticals, Inc. in October 2013.  EU Onyx Executives recognized that their experience, coupled with the commercialization infrastructure they had built, could be of extreme value to other companies entering Europe.  Their vision was to create a pioneering business model to commercialize products in ex-US by providing expertise, funding, and a commitment to build an ex-US presence on behalf of new biotech/pharma.